JMV 449Cat. No. 1998 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
Biological Activity
Potent, metabolically stable neurotensin receptor agonist peptide (IC50 = 0.15 nM for inhibition of [125I]-NT binding to neonatal mouse brain; EC50 = 1.9 nM for contraction of guinea pig ileum). Produces long-lasting hypothermic, neuroprotective and analgesic effects in mice following central administration in vivo.Technical Data
M.Wt:(Modifications: Lys-1 - Lys-2 peptide bond replace with Ψ(CH2-NH))
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Lugrin et al (1991) Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur.J.Pharmacol. 205 191. PMID: 1812009.
Dubuc et al (1992) JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur.J.Pharmacol. 219 327. PMID: 1425958.
Torup et al (2003) Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Neurosci.Lett. 351 173. PMID: 14623134.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: JMV 449, supplier, Potent, neurotensin, receptor, agonists, NT, Receptors, JMV449
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.





